EXEL vs IQV · P/E 17, rev $628.7M vs P/E 23, rev $16.31B
Exelixis Inc (EXEL) versus IQVIA Holdings Inc (IQV) — a side-by-side from cached financials, not a winner call.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
IQVIA Holdings Inc (IQV) is a diagnostics & research company listed on US.
Latest reported EXEL revenue for 2026-07-03 was $628.7M. Net income was $212.1M. Revenue was up 2.9% from 2026-04-03 to 2026-07-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Latest reported IQV revenue for 2025-12-31 was $16.31B. Net income was $1.36B. Revenue was up 5.9% from 2024-12-31 to 2025-12-31. IQV currently screens at market cap $30.62B and trailing P/E 22.8.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. IQV currently screens at market cap $30.62B and trailing P/E 22.8.
Not investment advice. Open the EXEL and IQV stock pages for the full models.
Not investment advice.